Biotech Stock Mailbag: Zalicus, Amarin
BOSTON (TheStreet) --I have a lot more to say about Amarin in this week's Biotech Stock Mailbag. The Hostile React-o-Meter spun outta control (!!!) in response to my column Wednesday discussing the high-level meeting that took place in June between FDA and Amarin executives.
Before I dive back into Amarin, however, let's discuss Zalicus and the announcement that's expected soon of results from a mid-stage study of its rheumatoid arthritis drug Synavive.
@delta4_98 tweets, "Adam, I am curious to hear your opinion on ZLCS Synavive AR." ...Click to view a price quote on AMRN. Click to research the Drugs industry.
Original Article: Biotech Stock Mailbag: Zalicus, AmarinNEXT ARTICLE